Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
29 nov. 2023 07h30 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to...
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
28 nov. 2023 07h00 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to...
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
16 nov. 2023 08h30 HE
|
Apollomics Inc.
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
31 oct. 2023 08h30 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address...
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
26 oct. 2023 08h50 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Institute of Oncology on the efficacy response of a...
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
23 oct. 2023 08h30 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG...
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
16 oct. 2023 18h55 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to...
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
28 sept. 2023 16h17 HE
|
Apollomics Inc.
Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash,...
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 07h00 HE
|
Apollomics Inc.
FOSTER CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to...
Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
11 avr. 2023 08h30 HE
|
Apollomics, Inc.
FOSTER CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address...